Treatment of Cheyne–Stokes respiration–central sleep apnea in patients with heart failure  by Momomura, Shin-ichi
JR
T
s
S
S
R
C
O
0
dournal of Cardiology (2012) 59,  110—116
Available  online  at  www.sciencedirect.com
j our na l ho me  page: www.elsev ier .com/ locate / j j cc
eview
reatment  of  Cheyne—Stokes  respiration—central
leep  apnea  in  patients  with  heart  failure
hin-ichi  Momomura  (MD,  PhD,  FJCC) ∗
aitama  Medical  Center,  Jichi  Medical  University,  Saitama,  Japan
eceived  19  December  2011;  accepted  22  December  2011
KEYWORDS
Central  sleep  apnea;
Cheyne—Stokes
respiration;
Oxygen  therapy;
Continuous  positive
airway  pressure;
Adaptive
Summary  Sleep  disordered  breathing  including  obstructive  sleep  apnea  (OSA)  and  central
sleep apnea  (CSA)  with  Cheyne—Stokes  respiration  (CSR)  is  often  accompanied  by  heart  fail-
ure. Treatment  of  OSA  centered  on  continuous  positive  airway  pressure  (CPAP)  is  established.
However, treatment  of  CSR-CSA  is  still  controversial.  Since  CSR-CSA  occurs  as  a  consequence  of
heart failure,  optimization  of  heart  failure  is  essential  to  treat  CSR-CSA.  For  treatment  directed
at CSR-CSA  itself,  a  variety  of  treatment  approaches  including  night  oxygen  therapy  and  non-
invasive positive  pressure  ventilation  have  been  applied.  Among  them,  night  oxygen  therapy
improves  patients’  symptoms,  quality  of  life  (QOL),  and  left  ventricular  function,  but  had  yet
been shown  to  improve  clinical  outcome.  For  CPAP,  there  are  responders  and  non-respondersservo-ventilation
and for  responders  CPAP  can  also  improve  survival.  Adaptive  servo-ventilation  (ASV),  which
most effectively  treats  CSR-CSA,  improves  exercise  capacity,  QOL,  and  cardiac  function.  Recent
reports suggested  ASV  may  also  prevent  cardiac  events  in  patients  with  heart  failure.  However,
further studies  are  needed  to  conclude  that  this  treatment  improves  patient  survival.
© 2012  Published  by  Elsevier  Ltd  on  behalf  of  Japanese  College  of  Cardiology.
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of  heart  failure  itself  ﬁrst  of  all.  Especially,  beta-blockers
improve  CSR-CSA  as  well  as  heart  failure  itself.  Tamura  et  al.
reported  induction  of  beta-blocker,  carvedilol,  improves
Table  1  Treatment  of  Cheyne—Stokes  respiration—central
sleep  apnea  with  heart  failure.
1.  Evidence  based  treatment  of  heart  failure
2. Continuous  positive  airway  pressure
3.  Non-invasive  positive  pressure  ventilation  (adaptive
servo-ventilation,  bi-level-positive  airway  pressure)
4. Night  oxygen  inhalation
5.  Carbon  dioxide  inhalation
6. TheophyllineIntroduction
Recent  advances  in  management  of  heart  failure  have
greatly  improved  prognosis  of  patients  with  this  syndrome.
However,  the  mortality  rate  of  heart  failure  is  still  not  low.
Among  Japanese  patients  with  heart  failure,  the  annual  mor-
tality  rate  is  7—8%  [1,2]. It  is  known  that  sleep  disordered
breathing  is  often  complicated  with  heart  failure.
There  are  two  types  of  sleep  apnea,  obstructive  sleep
apnea  (OSA)  and  central  sleep  apnea  (CSA).  OSA  is  a  common
disease  and  its  prevalence  is  high  in  the  normal  popula-
tion.  OSA  occurs  due  to  obstruction  of  upper  airway  and
closely  related  life  style  such  as  overweight,  smoking,  and
alcohol  drinking.  OSA  is  associated  with  many  cardiovascu-
lar  diseases  including  hypertension,  coronary  heart  disease,
arrhythmia,  aortic  dissection  pulmonary  hypertension,  and
heart  failure.
On  the  other  hand  CSA  is  due  to  loss  of  respiratory  drive
from  the  respiratory  center  and  is  rare  among  the  general
population.  While  on  the  other  hand,  among  a  variety  of
cardiovascular  diseases,  heart  failure  is  the  only  one  which
often  accompanies  CSA.  CSA  in  the  cardiovascular  ﬁeld,
shares  a  common  mechanism  with  Cheyne-Stoke  respiration,
a  weaning  and  waxing  periodical  breathing  which  is  observed
also  during  waking  in  patients  with  heart  failure.  There-
fore,  CSA  and  CSR  are  usually  combined  as  CSR-CSA.  CSR-CSA
occurs  as  a  consequence  of  heart  failure.  Either  type  of  sleep
disordered  breathing  worsens  the  prognosis  of  patients  with
heart  failure  [3,4]. However,  the  relationship  to  heart  fail-
ure  is  different  between  OSA  and  CSA.  OSA  locates  upstream
of  heart  failure,  and  is  important  as  a  risk  factor  for  car-
diovascular  disease.  On  the  other  hand,  CSR-CSA  locates
downstream  of  heart  failure  and  it  plays  an  important  role
in  the  progression  of  heart  failure.  Yumino  et  al.  compared
background  of  OSA  and  CSR-CSA,  and  reported  that  patients
with  CSA  are  older,  thinner,  had  lower  EF,  and  more  severe
New  York  Heart  Association  (NYHA)  class  [5].  Bitter  et  al.
reported  that  in  patients  with  diastolic  dysfunction  with
an  increasing  impairment  of  diastolic  function  the  propor-
tion  of  sleep  disordered  breathing,  and  CSA  in  particular,
increased  [6].  Thus  CSA  is  accompanied  with  more  severe
heart  failure.  This  coincides  with  the  fact  that  CSA  occurs
as  a  consequence  of  heart  failure,  while  OSA  can  impair
myocardial  contractility  and  cause  development  and  pro-
gression  of  heart  failure  [7].  Treatment  of  OSA  centering  on
continuous  positive  airway  pressure  (CPAP)  is  established.
However,  treatment  of  CSR-CSA  has  not  been  established
yet.
In  this  article,  treatment  of  CSR-CSA  will  be  the  focus.Mechanism of CSR-CSA in heart failure
In  patients  with  heart  failure,  pulmonary  congestion  occurs.
Pulmonary  congestion  leads  to  hyperventilation  throughulmonary  vagal  reﬂex.  Hypoxemia  with  pulmonary  conges-
ion  or  pulmonary  edema  also  exacerbates  hyperventilation.
s  a  result  of  hyperventilation,  hypocapnea  is  induced.
hemoreceptors  detect  hypocapnea  and  suppress  neuronal
rive  from  the  respiratory  center.  In  normal  subjects,  this
eedback  mechanism  normalizes  hypocapnea  and  respira-
ion  is  stabilized.  However,  in  patients  with  heart  failure,  the
hemoreceptor  response  is  enhanced  because  of  elevated
ympathetic  tone  and  excessive  respiratory  suppression  due
o  over  correction  by  the  chemoreceptor,  which  brings  about
pnea.  Once  respiration  ceases,  blood  carbon  dioxide  is
ncreased  and  hyperventilation  occurs  again,  thus  hyperven-
ilation  and  apnea/hypopnea  are  repeated.
Prolonged  circulation  time  due  to  low  cardiac  output  in
eart  failure  also  contributes  to  the  development  of  CSR-
SA.  Delivery  of  information  of  blood  gases  such  as  blood  CO2
nd  O2 to  the  chemoreceptor  is  delayed  due  to  prolonged
irculation  time  and  this  in  turn  delays  feedback  input  to
he  respiratory  center.
Recently,  Yumino  et  al.  demonstrated  that  nocturnal  ros-
ral  ﬂuid  shift  is  also  contributing  to  the  pathogenesis  of  CSA
s  well  as  OSA  in  patients  with  heart  failure  [8].  This  ﬂuid
hift  is  also  important  as  a  trigger  and  maintaining  factor  of
SR-CSA.
reatment of CSA
here  are  reported  to  be  many  treatment  approaches  to
SR-CSA,  including  optimization  of  heart  failure  treatment,
ight  oxygen  therapy,  positive  pressure  ventilation,  etc.
Table  1,  Fig.  1).
Treatment  of  heart  failure  seems  to  be  most  important
n  the  treatment  of  CSR-CSA.  Since  CSR-CSA  occurs  as  a
esult  of  heart  failure,  it  is  essential  to  optimize  treatment7. Acetazolamide
8. Phrenic  nerve  stimulation
9.  Atrial  overdrive  pacing
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Figure  1  Algorithm  for  the  treatment  of  sleep  disordered  breathing  in  patients  with  heart  failure.  HF,  heart  failure;  SDB,  sleep
disordered breathing;  OSA,  obstructive  sleep  apnea;  CSR-CSA,  Cheyne—Stokes  respiration—central  sleep  apnea;  PSG,  polysomnog-
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raphy; AHI,  apnea-hypopnea  index;  CPAP,  continuous  positive  ai
ressure; HOT,  home  oxygen  therapy.
SR-CSA  but  not  OSA  in  patients  with  heart  failure  due  to
eft  ventricular  (LV)  systolic  dysfunction.
Diuretics  could  also  improve  CSR-CSA  by  alleviating  pul-
onary  congestion  which  is  the  initial  event  of  the  sequence
rom  heart  failure  to  CSR-CSA.  Acetazolamide,  is  reported
o  improve  CSR-CSA  in  patients  with  CSR-CSA.  The  mecha-
ism  of  the  effect  of  acetazolamide  is  ﬁrstly  its  respiratory
timulating  effect  and  secondly  its  diuretic  effect.  However
cetazolamide  is  not  a  ﬁrst-line  diuretic  for  the  treatment  of
eart  failure.  Furosemide  is  the  most  widely  used  diuretic
or  the  treatment  of  heart  failure.  However,  so  far  there
s  no  report  which  demonstrated  that  furosemide  improves
SR-CSA,  although  it  improved  OSA  [9].  In  patients  with
eart  failure,  body  ﬂuid  shifts  to  upper  body  while  patient
s  sleeping  at  night.  This  ﬂuid  shift  may  contribute  to  the
evelopment  of  CSA  by  enhancing  pulmonary  congestion,  a
rigger  of  the  sequence  of  CSR-CSA  as  well  as  OSA  by  increas-
ng  airway  edema  (nocturnal  rostral  ﬂuid  shift  is  a  unifying
oncept  for  the  pathogenesis  of  OSA  and  CSA  in  men  with
eart  failure)  [8].  Therefore  normalization  of  ﬂuid  status
ith  diuretics  in  patients  with  heart  failure  is  essential.heophylline
heophylline  stimulates  respiration  by  competing  with
denosine,  a  respiratory  depressant  and  improves  sleep
h
3
S
C pressure;  ASV,  adaptive  servo-ventilation;  PAP,  positive  airway
isordered  breathing,  although  the  entire  mechanism
hrough  which  this  drug  improves  sleep  apnea  is  not  fully
nderstood.
Many  years  ago,  Javaheri  reported  the  short-term  effect
f  theophylline  on  CSR-CSA  [10]. This  effect  of  theophylline
as  attested  by  Hu  et  al.  in  an  Asian  population  with  heart
ailure  [11]. Theophylline  also  has  a  positive  inotropic  effect
hrough  phosphodiesterase  III  inhibitory  action.  However,
very  drug  which  has  positive  inotropic  effects  including
hosphodiesterase  inhibitors  has  a  negative  impact  on  mor-
ality  in  patients  with  chronic  heart  failure  due  to  depressed
V  dysfunction.  Thus  theophylline  is  not  recommended  for
atients  with  heart  failure  especially  due  to  LV  systolic  dys-
unction.
on-pharmacological treatment of heart
ailure
on-pharmacological  treatment  of  heart  failure  also
mproves  CSR-CSA.  In  2004,  Sinha  et  al.  reported  that
esynchronization  brought  a signiﬁcant  decrease  in  apnea-
ypopnea  index  (AHI)  and  sleep  quality  index  (10.4  ±  1.6  to
.9  ±  2.4,  p  <  0.001)  without  CSR  and  a  signiﬁcant  increase  in
aO2  min  (84  ±  5%  to  89  ±  2%,  p  <  0.001)  in  14  patients  with
SR-CSA,  while  there  was  no  signiﬁcant  change  in  AHI,  and
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SaO2  min  in  patients  without  CSA  [12]. This  ﬁnding  is  sup-
ported  by  a  recent  meta-analysis  [13]. In  this  meta-analysis,
170  patients  from  six  manuscripts  and  three  abstracts  were
included.  After  treatment  with  cardiac  resynchronization
therapy,  a  signiﬁcant  reduction  in  AHI  was  found  in  patients
with  CSA  with  a  mean  reduction  of  −13.05  (CI  −16.74  to
−9.36;  p  <  0.00001)  but  not  in  patients  with  OSA.
Atrial overdrive pacing
In  2002,  Garrigue  reported  that  atrial  pacing  improves
CSR-CSA  as  well  as  OSA  [14]  in  patients  with  pacemaker
implantation  because  of  the  treatment  of  bradycardia.
Meta-analysis  also  showed  that  overdrive  atrial  pacing
reduces  AHI  in  patients  with  predominantly  CSA  [15]. How-
ever  the  additional  effect  of  atrial  overdrive  pacing  on
CSR-CSA  in  patients  with  heart  failure  was  only  small  [16].
Thus  atrial  overdrive  pacing  should  not  be  applied  simply  to
treat  CSR-CSA.
Home oxygen therapy
Originally  in  1989,  Hanly  et  al.  reported  that  the  acute  effect
of  nocturnal  oxygen  therapy  on  CSR  corrects  hypoxemia,  and
consolidates  sleep  by  reducing  arousals  caused  by  the  hyper-
pneic  phase  of  CSR  [17]. A  decade  after  the  ﬁrst  report  by
Hanly,  Javaheri  also  reported  that  oxygen  inhalation  acutely
improved  CSR  in  patients  with  heart  failure  and  this  effect
of  oxygen,  however,  may  be  modulated  by  the  level  of  arte-
rial  PCO2  [18]. However  in  these  studies  the  effects  of
oxygen  inhalation  to  indexes  of  heart  failure,  including  ejec-
tion  fraction  and  NYHA  class  were  not  evaluated.  In  1996,
Andreas  et  al.  demonstrated  that  successful  treatment  of
CSR  with  nocturnal  nasal  oxygen  improves  not  only  sleep,  but
also  exercise  tolerance  and  cognitive  function  in  patients
with  congestive  heart  failure  [19]. More  recently,  three  ran-
domized  studies  were  presented  from  Japan  [20,21].  In  the
short-term  study  by  Sasayama  et  al.,  night  oxygen  inhala-
tion  improved  CSR-CSA  as  well  as  LV  function  and  quality  of
life  assessed  by  speciﬁc  activity  scale.  In  the  1-year  study,
home  oxygen  therapy  (HOT)  was  well  tolerated  and  the
beneﬁt  on  LV  function  and  quality  of  life  observed  in  the  12-
week  trial  was  maintained  over  a  prolonged  period  although
this  study  failed  to  show  beneﬁt  on  the  primary  compos-
ite  cardiac  endpoints  of  combined  rate  of  cardiac  death,
hospitalization  because  of  worsening  heart  failure,  and  a
decrease  in  the  Speciﬁc  Activity  Scale  by  ≥1  Mets,  because
of  the  small  sample  size.  Another  randomized  study  reported
by  Japanese  researchers  demonstrated  that  HOT  improves
exercise  capacity,  cardiac  function,  and  cardiac  sympathetic
nerve  activity  in  patients  with  congestive  heart  failure  and
CSA  [22]. Thus,  in  Japan,  HOT  is  approved  for  reimburse-
ment  by  public  health  insurance  in  patients  with  NYHA  class
III  or  IV,  with  optimal  medical  therapy  for  heart  failure  and
AHI  higher  than  20  by  polysomnography.The  mechanism  of  night  oxygen  therapy  is  not  fully
understood,  but  by  maintaining  PO2  level  with  night  oxygen
therapy  sympathetic  hyperactivity  is  alleviated  [23]  and  may
normalize  VE/PCO2  relationship  in  CSR.
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ontinuous positive airway pressure
PAP  was  originally  a  standard  treatment  for  OSA  by  sup-
lying  pressure  higher  than  the  obstructive  pressure  of  the
irway  and  not  speciﬁcally  designed  to  treat  CSR-CSA.  How-
ver,  CPAP  may  also  reduce  CSR-CSA  in  patients  with  heart
ailure  through  its  unloading  effect.  CPAP  reduces  LV  preload
y  supplying  positive  pressure  to  thoracic  cage  and  improves
ulmonary  congestion.  This  may  attenuate  hyperventilation
hrough  pulmonary  vagal  irritant  receptors  and  subsequent
SR.  In  fact  in  2000,  Sin  et  al.  reported  the  results  of  a
andomized  study.  In  this  study  CPAP  improved  survival  in
atients  with  heart  failure  and  CSR-CSA  [24]. This  has  led
o  the  CANPAP,  a  large-scale  randomized  study  to  evaluate
he  effect  of  CPAP  on  survival  in  patients  with  heart  failure
omplicated  with  CSR-CSA  [25]. As  is  well  known,  although
PAP  did  not  improve  survival  it  attenuated  CSA,  improved
octurnal  oxygenation,  increased  the  ejection  fraction,  low-
red  norepinephrine  levels,  and  increased  exercise  capacity
valuated  by  6  min  walk  distance.  Sub-analysis  of  CANPAP  by
rzt  et  al.  had  some  positive  impact  [26]. In  57  patients  out
f  110  in  the  CPAP  group,  AHI  was  improved  to  below  15.
n  this  group,  CPAP  treatment  resulted  in  a  greater  increase
n  LV  ejection  fraction  at  3  months  and  signiﬁcantly  bet-
er  transplant-free  survival  than  control  subjects,  whereas
n  the  rest  of  the  patients,  whose  AHI  remained  above  15,
either  LV  ejection  fraction  or  survival  was  improved.  Thus
here  are  ‘‘responders’’  and  ‘‘non-responders’’  to  CPAP
n  heart  failure  patients  with  CSR-CSA.  ‘‘Non-responders’’
re  older,  had  more  severe  sleep  disordered  breathing,
nd  a  larger  fraction  of  central  component  compared  with
‘responders’’.  Five  years  before  the  results  of  CANPAP  were
ublished,  Javaheri  reported  that  there  are  responsive  and
on-responsive  patients  whose  CSA  was  acutely  treated  by
PAP  [27]. Moreover  non-responsive  patients  had  higher  AHI
nd  more  pure  CSA.  Thus,  CPAP  has  a  limited  effect  on  the
reatment  of  patients  with  heart  failure  and  CSR-CSA.
on-invasive positive pressure ventilation
i-level  positive  airway  pressure  (PAP)  was  originally  used  to
reat  patients’  respiratory  failure  and  supply  oblong  pres-
ure  support  to  forcibly  ventilate  these  patients.  On  the
ssumption  that  bi-level  PAP  may  also  treat  CSR-CSA,  clin-
cal  studies  were  performed  in  heart  failure  patients  with
SR-CSA.  Dohi  et  al.  treated  20  heart  failure  patients  with
SR-CSA  ﬁrst  with  CPAP  for  one  night  and  then  with  bi-level
AP  in  11  patients  in  whom  AHI  remained  >15  with  CPAP.
hose  who  were  unresponsive  to  CPAP  had  signiﬁcantly  lower
CO2, higher  plasma  brain  natriuretic  peptide  (BNP),  longer
ean  duration  of  CSR  and  fewer  obstructive  episodes  than
PAP  responders.  Among  these  11  patients,  7  were  chroni-
ally  treated  with  bi-level  PAP  for  6  months  with  improved
V  ejection  fraction  [28]. Thus  they  concluded  bi-level  PAP
ould  be  an  effective  alternative  for  patients  with  heart  fail-
re  and  pure  CSR-CSA  who  are  unresponsive  to  CPAP.  Kasai
reated  7  heart  failure  patients  complicated  with  CSR-CSA
ith  bi-level  PAP  and  compared  with  the  same  number  of
atients  with  conventional  therapy.  Bi-level  PAP  signiﬁcantly
mproved  LV  ejection  fraction,  mitral  regurgitation,  BNP,  and
YHA  class  [29]. Similarly,  Noda  et  al.  treated  52  dilated
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ardiomyopathy  patients  with  coexisting  CSR-CSA  with  bi-
evel  PAP  and  found  that  bi-level  PAP  improves  LV  function
s  well  as  CSR-CSA  [30]. Thus  bi-level  PAP  is  more  effective
han  CPAP  in  treating  CSR-CSA  and  improves  LV  function.
owever  the  problem  of  bi-level  PAP  was  its  low  compliance,
nd  it  could  not  be  taken  over  CPAP.
daptive servo-ventilation
o  date,  the  most  effective  treatment  for  CSR-CSA  is  adap-
ive  servo-ventilation  (ASV).  Teschler  et  al.  compared  the
ffect  of  one  night  of  ASV  on  sleep  and  breathing  with  the
ffect  of  other  treatment  modalities  including  nasal  oxy-
en  (2  L/min),  CPAP  (mean  9.25  cm  H2O),  bi-level  PAP  (mean
3.5/5.2  cm  H2O),  or  ASV  largely  at  the  default  settings
mean  pressure  7—9  cm  H2O)  during  polysomnography  in  14
ubjects  with  stable  cardiac  failure  and  receiving  optimal
edical  treatment.  These  four  treatment  modalities  were
ested  on  four  treatment  nights  in  random  order.  They  found
hat  one  night  ASV  more  strongly  suppresses  CSA  and/or  CSR
CSA/CSR)  in  heart  failure  and  improves  sleep  quality  bet-
er  than  any  other  treatment  modalities  [31]. Since  then,
n  increasing  number  of  reports  on  ASV  effects  in  patients
ith  heart  failure  and  sleep  disordered  breathing  have  been
ublished  [32—38].
Pepperell  demonstrated  signiﬁcant  falls  in  plasma  BNP
nd  urinary  metadrenaline  excretion  with  1  month  active
reatment  compared  with  subtherapeutic  patients  [32]. Old-
nburg  demonstrated  that  ASV  improved  indexes  of  exercise
apacity  including  anaerobic  threshold  (AT),  peak  oxygen
ptake,  and  peak  workload  as  well  as  improvement  in  LV
jection  fraction  and  blood  N  terminal  pro-BNP  level  in
atients  with  heart  failure  due  to  LV  systolic  dysfunction
39].
The  effect  of  ASV  is  not  limited  to  heart  failure  patients
ith  reduced  LV  ejection  fraction  but  extended  to  those  with
reserved  LV  ejection  fraction.  Bitter  et  al.  reported  ASV
ffectively  attenuates  CSR  in  39  patients  with  heart  failure
nd  normal  LV  ejection  fraction  and  improves  heart  fail-
re  symptoms  and  cardiac  function,  especially  echo-Doppler
ndexes  of  diastolic  function  [40]. Superiority  of  ASV  to  other
reatments  has  also  been  reported.  Phillipe  et  al.  random-
zed  patients  to  ASV  and  CPAP  [33]. They  found  that  both
SV  and  CPAP  decreased  the  AHI  but,  noticeably,  only  ASV
ompletely  corrected  CSA—CSR,  with  AHI  below  10  h−1. At
 months,  compliance  was  comparable  between  ASV  and
PAP;  however,  at  6  months  compliance  with  CPAP  was  sig-
iﬁcantly  less  than  with  ASV.  At  6  months,  the  improvement
n  quality  of  life  was  higher  with  ASV  and  only  ASV  induced  a
igniﬁcant  increase  in  LV  ejection  fraction.  Campbell  et  al.
ompared  two  treatments  for  CSA—CSR,  night  oxygen  ther-
py  and  ASV  in  patients  with  chronic  heart  failure  using  a
ross  over  design  [41]. They  found  that  CSA—CSR  is  reduced
o  a  greater  extent  by  ASV  than  oxygen  therapy  over  8  weeks
ut  was  not  accepted  long  term.  However,  neither  treatment
mproved  prognostic  indices  of  heart  failure  or  symptoms  in
he  short  term.  Eight  weeks  was  probably  too  short  to  show
mprovement  in  LV  function  for  both  treatment  modalities.
Another  type  of  ASV  (auto  servo-ventilation)  also  effec-
ively  treats  CSR-CSA  [42]. Kasai  et  al.  reported  the  results
f  randomized  study,  J-ASV,  of  this  device  in  comparison
P
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ith CPAP  in  patients  with  chronic  heart  failure  and  coex-
sting  CSR-CSA  and  OSA  [43]. In  this  study,  31  patients
ith  chronic  heart  failure,  deﬁned  as  LV  ejection  frac-
ion  <50%  and  NYHA  class  ≥II,  with  coexisting  obstructive
leep  apnea  and  CSR-CSA,  were  randomly  assigned  to  either
PAP  or  ﬂow-triggered  ASV.  The  suppression  of  respiratory
vents,  changes  in  cardiac  function,  and  compliance  with
he  devices  during  the  3-month  study  period,  improvements
n  quality-of-life  and  LV  ejection  fraction  were  greater  in
he  ASV  group.  Compliance  was  signiﬁcantly  greater  with
SV  than  with  CPAP  and  there  was  a  signiﬁcant  correlation
etween  machine  using  time  and  improvement  in  LV  ejec-
ion  fraction  when  data  from  both  groups  were  plotted  on
he  same  plane.
Thus  ASV  (adaptive  servo-ventilation  or  auto  servo-
entilation)  improves  cardiac  function,  exercise  capacity,
nd  quality  of  life,  but  its  effect  on  survival  in  patients
ith  heart  failure  is  unknown.  Recently,  Yoshihisa  reported
hat  clinical  events  including  cardiac  death  or  hospitaliza-
ion  are  signiﬁcantly  lower  in  heart  failure  treated  with
SV  compared  with  those  not  treated  with  ASV.  Koyama
t  al.  reported  that  the  effects  of  ASV  on  clinical  events
nd  LV  function  were  demonstrated  regardless  of  the  sever-
ty  of  sleep  apnea  [44]. Takama  reported  ASV  treatment
or  patients  with  mild  sleep  disordered  breathing  resulted
n  almost  equal  improvements  in  BNP  levels  and  LV  ejec-
ion  fraction  compared  to  that  in  patients  with  moderate
nd  severe  sleep  disordered  breathing  [45]. The  results  of
hese  reports  may  indicate  that  ASV  improves  heart  fail-
re  regardless  of  sleep  disordered  breathing.  However,  in
oyama’s  study,  AHI  in  two  groups  with  patients  with  non-to-
ild  sleep  disordered  breathing  were  14.2  and  15.6,  which
ere  actually  not  very  mild.  And  in  Takama’s  report,  the
mprovement  in  LV  ejection  fraction  was  relatively  mild  and
ot  signiﬁcant  in  the  mild  sleep  disordered  breathing  group
AHI,  20)  although  there  was  no  difference  in  the  LV  ejection
raction  after  ASV  therapy  between  the  groups.  But  these
eports  raise  the  question  if  the  mechanism  of  improvement
n  heart  failure  by  ASV  may  not  be  through  its  effect  on
leep  disordered  breathing.  Even  without  sleep  disordered
reathing,  ASV  decreases  LV  preload  and  afterload  by  sup-
lying  positive  intrathoracic  pressure.  Expansion  of  the  lung
y  breath-by-breath  pressure  support  of  ASV  may  amelio-
ate  the  increased  sympathetic  tone  in  patients  with  heart
ailure.
According  to  Haruki  et  al.  the  acute  beneﬁcial  impact
f  ASV  is  mainly  associated  with  the  reduction  of  afterload
esulting  in  an  increase  in  stroke  volume  and  cardiac  out-
ut.  In  contrast,  chronic  ASV  therapy  produces  LV  and  left
trial  reverse  remodeling  resulting  in  an  improvement  in  LV
unction  and  the  severity  of  mitral  regurgitation  in  patients
ith  chronic  heart  failure  [46]. These  effects  of  ASV  may
ell  be  exerted  without  direct  effect  on  sleep  disordered
reathing.
Two  randomized  trials  evaluating  the  effect  of  ASV  on
urvival  are  ongoing  currently.hrenic nerve stimulation
ecently  Ponikowski  et  al.  reported  that  unilateral
ransvenous  phrenic  nerve  stimulation  signiﬁcantly  reduces
a  in
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episodes  of  CSA  and  restores  a  more  natural  breathing  pat-
tern  in  patients  with  heart  failure  [47]. This  therapy  was
originally  used  to  provide  respiratory  support  in  patients
with  respiratory  paralysis  from  high  cervical  spinal  cord
injury  and  in  patients  with  central  alveolar  hypoventilation
syndrome  (Ondine’s  curse).  This  study  reports  the  results  of
only  a  single  night  of  therapy  involving  a  relatively  small
number  of  patients,  and  the  effect  of  chronic  phrenic  nerve
stimulation  which  needs  surgical  procedure  is  not  known.
CO2 administration
Giannoni  applied  a  novel  automated  algorithm  in  seven
patients  with  heart  failure  and  periodic  breathing  and  found
that  dynamic  CO2 administration,  delivered  at  an  appropri-
ate  time  during  periodic  breathing,  can  almost  eliminate
oscillations  in  end  tidal-CO2 and  ventilation.  This  dynamic
approach  might  be  developed  to  treat  CSA,  as  well  as  mini-
mizing  undesirable  increases  in  end  tidal-CO2 and  ventilation
[48].
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